Profile data is unavailable for this security.
About the company
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
- Revenue in GBP (TTM)0.00
- Net income in GBP-2.01m
- Incorporated2014
- Employees9.00
- LocationTheraCryf PLCSuite 24G13 - Block 24 Alderley ParkCongleton Road, Nether AlderleyNETHERTON SK10 4TGUnited KingdomGBR
- Phone+44 162 531 5090
- Websitehttps://theracryf.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roquefort Therapeutics PLC | 0.00 | -882.45k | 1.96m | 1.00 | -- | 0.3975 | -- | -- | -0.0063 | -0.0063 | 0.00 | 0.0302 | 0.00 | -- | -- | 0.00 | -15.04 | -- | -17.23 | -- | -- | -- | -- | -- | -- | -17.40 | 0.0747 | -- | -100.00 | -- | 44.29 | -- | -- | -- |
| ValiRx Plc | 49.78k | -1.78m | 2.56m | 14.00 | -- | 0.3742 | -- | 51.48 | -0.0094 | -0.0094 | 0.0002 | 0.0092 | 0.0147 | 0.00 | 0.6068 | 3,555.71 | -55.35 | -48.98 | -51.45 | -49.62 | 100.00 | -- | -3,775.95 | -16,086.59 | 8.87 | -- | 0.0022 | -- | 418.54 | -- | 5.99 | -- | -37.39 | -- |
| N4 Pharma PLC | 7.07k | -1.07m | 3.95m | 4.00 | -- | 2.24 | -- | 559.17 | -0.0025 | -0.0025 | 0.00002 | 0.0021 | 0.0045 | -- | 0.0756 | 1,767.50 | -71.04 | -59.59 | -74.91 | -63.90 | -- | -- | -15,981.33 | -67,987.22 | -- | -- | 0.00 | -- | 273.33 | -- | 16.60 | -- | -- | -- |
| TheraCryf PLC | 0.00 | -2.01m | 4.51m | 9.00 | -- | 0.9398 | -- | -- | -0.0017 | -0.0017 | 0.00 | 0.0022 | 0.00 | -- | -- | 0.00 | -41.20 | -38.70 | -53.79 | -42.97 | -- | -- | -- | -1,407.46 | -- | -- | 0.00 | -- | -100.00 | -- | 38.13 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.12m | 6.14m | 67.00 | -- | -- | -- | -- | -0.0028 | -0.0028 | 0.00 | -0.0007 | 0.00 | -- | -- | -- | -190.34 | -146.14 | -433.59 | -169.40 | -- | -- | -- | -- | 0.4766 | -2.42 | -- | -- | -- | -- | -26.15 | -- | -- | -- |
| Futura Medical PLC | 7.93m | -6.29m | 7.41m | 12.00 | -- | 1.27 | -- | 0.9351 | -0.0207 | -0.0207 | 0.0261 | 0.01 | 1.06 | 137.36 | 8.58 | -- | -84.19 | -45.00 | -112.42 | -71.79 | 70.67 | -- | -79.41 | -108.25 | 2.21 | -- | 0.00 | -- | 349.09 | 237.55 | 119.85 | -- | 121.02 | -- |
| OptiBiotix Health PLC | 1.15m | -191.00k | 7.90m | 5.00 | -- | 0.9385 | 564.46 | 6.87 | -0.0018 | -0.0018 | 0.0113 | 0.0815 | 0.134 | 1.93 | 2.88 | 230,200.00 | -2.22 | 17.23 | -2.33 | 17.84 | 45.44 | 50.78 | -16.59 | 189.34 | 3.75 | -- | 0.00 | 94.93 | 35.09 | 3.15 | 11.48 | -- | -- | -- |
| IXICO PLC | 6.53m | -1.65m | 9.50m | 79.00 | -- | 0.8093 | -- | 1.45 | -0.0186 | -0.0186 | 0.073 | 0.1267 | 0.5222 | -- | 3.18 | 82,708.86 | -13.19 | -3.47 | -15.43 | -4.03 | 48.71 | 55.52 | -25.27 | -6.21 | -- | -- | 0.015 | -- | 13.32 | -7.27 | 17.49 | -- | -5.30 | -- |
| Genflow Biosciences PLC | 0.00 | -1.80m | 10.86m | 5.00 | -- | -- | -- | -- | -0.005 | -0.005 | 0.00 | -0.0007 | 0.00 | -- | -- | 0.00 | -197.92 | -- | -648.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.68 | -- | -- | -- |
| Solvonis Therapeutics PLC | 0.00 | -2.60m | 16.34m | -- | -- | 2.04 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -44.49 | -- | -54.32 | -- | -- | -- | -- | -- | -- | -645.25 | 0.011 | -- | -100.00 | -- | 53.62 | -- | -- | -- |
| Fusion Antibodies PLC | 1.60m | -1.47m | 19.07m | 24.00 | -- | 23.87 | -- | 11.95 | -0.0144 | -0.0144 | 0.0152 | 0.0064 | 0.9557 | 4.96 | 1.96 | 66,500.00 | -87.84 | -56.24 | -137.88 | -73.67 | 22.06 | 36.41 | -91.92 | -71.05 | 1.45 | -190.63 | 0.3483 | -- | 72.98 | -12.79 | 23.05 | -- | -37.98 | -- |
Data as of Feb 06 2026. Currency figures normalised to TheraCryf PLC's reporting currency: UK Pound GBX
43.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fiske Plc (Broker)as of 01 Dec 2025 | 430.07m | 20.01% |
| First Equity Ltd.as of 29 May 2025 | 179.00m | 8.33% |
| IG Markets Ltd.as of 01 Dec 2025 | 91.29m | 4.25% |
| Oberon Investments Ltd. (GB Investment Management)as of 29 May 2025 | 80.48m | 3.75% |
| KW Investment Management Ltd.as of 01 Dec 2025 | 40.38m | 1.88% |
| Hargreaves Lansdown Fund Managers Ltd.as of 01 Dec 2025 | 33.26m | 1.55% |
| Rathbones Investment Management Ltd.as of 11 Mar 2025 | 24.83m | 1.16% |
| Rowan Dartington & Co. Ltd. (Broker)as of 01 Dec 2025 | 22.45m | 1.05% |
| Octopus Investments Ltd.as of 11 Mar 2025 | 21.88m | 1.02% |
| Vulpes Investment Management Pte Ltd.as of 11 Apr 2024 | 20.55m | 0.96% |
More ▼
Data from 31 Mar 2025 - 29 Jan 2026Source: FactSet Research Systems Inc.
